Embecta Corp. (EMBC)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1872789 · fiscal year ends in Sep
Closing price $6.25 on 30 Oct 2026; 52-week range $2.90 to $14.64.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $1.0B
- Revenue growth
- -7.6%
- Net income, last twelve months
- $87.5M
- Earnings per share
- $1.48
- Gross margin
- 59.0%
- Operating margin
- 21.9%
- Net margin
- 8.6%
- Free cash flow
- $164.6M
- Market value
- $354.1M
- Price to earnings
- 4.2x
- Dividend yield
- 7.4%
- Cash
- $214.7M
- Debt
- $1.5B
- Shares outstanding
- 56.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 30 Sep 2025 | $1.1B | $242.1M | $95.4M | $1.62 | $182.4M | 10-K filed 25 Nov 2025 |
| FY2024 | 30 Sep 2024 | $1.1B | $166.8M | $78.3M | $1.34 | $19.9M | 10-K filed 11 Dec 2024 |
| FY2023 | 30 Sep 2023 | $1.1B | $221.5M | $70.4M | $1.22 | $41.2M | 10-K filed 29 Nov 2023 |
| FY2022 | 30 Sep 2022 | $1.1B | $309.6M | $223.6M | $3.89 | $388.6M | 10-K filed 22 Dec 2022 |
| FY2021 | 30 Sep 2021 | $1.2B | $492.0M | $414.8M | $7.28 | $419.5M | 10-K filed 22 Dec 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Jun 2026 | $271.7M | $21.1M | $0.36 |
| Q2 FY2026 | 31 Mar 2026 | $221.8M | -$4.1M | -$0.07 |
| Q1 FY2026 | 31 Dec 2025 | $261.2M | $44.1M | $0.74 |
| Q4 FY2025 | 30 Sep 2025 | $264.0M | $26.4M | $0.45 |
| Q3 FY2025 | 30 Jun 2025 | $295.5M | $45.5M | $0.78 |
| Q2 FY2025 | 31 Mar 2025 | $259.0M | $23.5M | $0.40 |
| Q1 FY2025 | 31 Dec 2024 | $261.9M | $0 | $0.00 |
| Q4 FY2024 | 30 Sep 2024 | $286.1M | $14.6M | $0.25 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Pen Needles | $784.1M | 72.6% |
| Safety | $137.8M | 12.8% |
| Syringes | $124.6M | 11.5% |
| Contract Manufacturing | $19.9M | 1.8% |
| Other | $14.0M | 1.3% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $579.1M | 53.6% |
| International | $501.3M | 46.4% |
Company events
The newest 8-K filings of 38 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 7 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 15 May 2026 | 8-K | Deal completed, Investor update | 2.01, 7.01, 9.01 |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Mar 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 13 Feb 2026 | 8-K | Shareholder vote | 5.07 |
| 5 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 25 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 17 Nov 2025 | 8-K | Leadership change | 5.02, 9.01 |
| 8 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 22 May 2025 | 8-K | Investor update | 7.01, 9.01 |
| 9 May 2025 | 8-K | Results | 2.02, 9.01 |
| 14 Feb 2025 | 8-K | Shareholder vote | 5.07 |
Every filing
The newest filings with the SEC of 93 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | S-8 | – |
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
| 31 Jul 2026 | 8-K/A | 15 May 2026 |
| 22 May 2026 | SD | – |
| 15 May 2026 | 8-K | 15 May 2026 |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 20 Mar 2026 | 8-K | 19 Mar 2026 |
| 13 Feb 2026 | 8-K | 11 Feb 2026 |
| 5 Feb 2026 | 10-Q | 31 Dec 2025 |
| 5 Feb 2026 | 8-K | 5 Feb 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 4 Sep 2026 | Morris Milton Mayo, Director | Sale outside a trading plan | 6,293 | $5.88 | $37.0K | 53,828 | 8 Sep 2026 |
| 12 Aug 2026 | Kurdikar Devdatt, President and CEO | Purchase | 30,000 | $4.70 | $140.9K | 804,919 | 13 Aug 2026 |
| 12 Aug 2026 | Elguicze Jacob, SVP and CFO | Purchase | 20,000 | $4.67 | $93.4K | 309,139 | 13 Aug 2026 |
| 12 Aug 2026 | Mann Jeffrey Z, Pres, Pharm Svc&Prod Mgmt, CLO | Purchase | 20,000 | $4.99 | $99.8K | 262,915 | 13 Aug 2026 |
| 12 Aug 2026 | Hombach Robert J., Director | Purchase | 45,000 | $4.97 | $223.8K | 109,587 | 13 Aug 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 4 Sep 2026 | Morris Milton Mayo, Director | 6,293 | $36.9K | 4 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | American Century Investment Management, Inc. | 13G amended | 0% | 154 |
| 8 Jul 2026 | BlackRock, Inc. | 13G amended | 7.7% | 4.6M |
| 27 May 2026 | River Road Asset Management, LLC | 13G amended | 0% | 0 |
| 5 May 2026 | YACKTMAN ASSET MANAGEMENT LP | 13G | 6.2% | 3.7M |
| 1 May 2026 | American Century Capital Portfolios, Inc. | 13G amended | 5.8% | 3.4M |
| 29 Apr 2026 | Vanguard Capital Management | 13G | 5.07% | 3.0M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 30 Jan 2026 | The Vanguard Group | 13G amended | 7.79% | 4.6M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 5.9M | +0.76% | 6.16 |
| 30 Sep 2026 | 5.8M | +5.01% | 5.43 |
| 15 Sep 2026 | 5.5M | -11.45% | 4.46 |
| 31 Aug 2026 | 6.3M | +15.08% | 4.64 |
| 14 Aug 2026 | 5.4M | -18.52% | 2.46 |
| 31 Jul 2026 | 6.7M | +10.88% | 5.87 |
| 15 Jul 2026 | 6.0M | +3.09% | 3.9 |
| 30 Jun 2026 | 5.8M | -15.96% | 1.76 |
Funds that hold it
From each fund's latest Form 13F.
396 funds held it at 30 Jun 2026: 130 added and 74 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 4,599,771 | $15.0M | -4,567,441 |
| Yacktman Asset Management LP | 4,315,952 | $14.1M | +644,075 |
| Vanguard Capital Management LLC | 2,557,148 | $8.3M | -6,803 |
| Deerfield Management Company, L.P. | 2,534,961 | $8.3M | 0 |
| Jefferies Financial Group Inc. | 2,355,117 | $7.7M | -45 |
| Ameriprise Financial Inc. | 2,038,731 | $6.6M | +1,239,043 |
| Morgan Stanley | 1,996,747 | $6.5M | +1,386,943 |
| State Street Corp. | 1,610,666 | $5.3M | -935,307 |
| Geode Capital Management, LLC | 1,594,457 | $5.2M | +128,810 |
| Brigade Capital Management, LP | 1,516,453 | $4.9M | +1,516,453 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B